Standard

Metabolomic biomarkers in gynecology : A treasure path or a false path? / Govorov, Igor; Sitkin, Stanislav; Pervunina, Tatyana; Moskvin, Alexey; Baranenko, Denis; Komlichenko, Eduard.

In: Current Medicinal Chemistry, Vol. 27, No. 22, 2020, p. 3611-3622.

Research output: Contribution to journal › Review article › peer-review

Harvard

Govorov, I, Sitkin, S, Pervunina, T, Moskvin, A, Baranenko, D & Komlichenko, E 2020, 'Metabolomic biomarkers in gynecology: A treasure path or a false path?', Current Medicinal Chemistry, vol. 27, no. 22, pp. 3611-3622. https://doi.org/10.2174/0929867326666190104124245

APA

Govorov, I., Sitkin, S., Pervunina, T., Moskvin, A., Baranenko, D., & Komlichenko, E. (2020). Metabolomic biomarkers in gynecology: A treasure path or a false path? Current Medicinal Chemistry, 27(22), 3611-3622. https://doi.org/10.2174/0929867326666190104124245

Vancouver

Govorov I, Sitkin S, Pervunina T, Moskvin A, Baranenko D, Komlichenko E. Metabolomic biomarkers in gynecology: A treasure path or a false path? Current Medicinal Chemistry. 2020;27(22):3611-3622. https://doi.org/10.2174/0929867326666190104124245

Author

Govorov, Igor ; Sitkin, Stanislav ; Pervunina, Tatyana ; Moskvin, Alexey ; Baranenko, Denis ; Komlichenko, Eduard. / Metabolomic biomarkers in gynecology : A treasure path or a false path?. In: Current Medicinal Chemistry. 2020 ; Vol. 27, No. 22. pp. 3611-3622.

BibTeX

@article{ceed13e73dc848fb99b76dbd8cf76d0e,
title = "Metabolomic biomarkers in gynecology: A treasure path or a false path?",
abstract = "Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.",
keywords = "Biomarkers, Endometriosis, Gynecology, Leiomyoma, Metabolomics, Ovarian neoplasms, Polycystic ovary syndrome, Uterine cervical neoplasms",
author = "Igor Govorov and Stanislav Sitkin and Tatyana Pervunina and Alexey Moskvin and Denis Baranenko and Eduard Komlichenko",
note = "Publisher Copyright: {\textcopyright} 2020 Bentham Science Publishers.",
year = "2020",
doi = "10.2174/0929867326666190104124245",
language = "English",
volume = "27",
pages = "3611--3622",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "22",

}

RIS

TY - JOUR

T1 - Metabolomic biomarkers in gynecology

T2 - A treasure path or a false path?

AU - Govorov, Igor

AU - Sitkin, Stanislav

AU - Pervunina, Tatyana

AU - Moskvin, Alexey

AU - Baranenko, Denis

AU - Komlichenko, Eduard

N1 - Publisher Copyright: © 2020 Bentham Science Publishers.

PY - 2020

Y1 - 2020

N2 - Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.

AB - Omic-technologies (genomics, transcriptomics, proteomics and metabolomics) have become more important in current medical science. Among them, it is metabolomics that most accurately reflects the minor changes in body functioning, as it focuses on metabolome – the group of the metabolism products, both intermediate and end. Therefore, metabolomics is actively engaged in fundamental and clinical studies and search for potential biomarkers. The biomarker could be used in diagnostics, management and stratification of the patients, as well as in prognosing the outcomes. The good example is gynecology, since many gynecological diseases lack effective biomarkers. In the current review, we aimed to summarize the results of the studies, devoted to the search of potential metabolomic biomarkers for the most common gynecological diseases.

KW - Biomarkers

KW - Endometriosis

KW - Gynecology

KW - Leiomyoma

KW - Metabolomics

KW - Ovarian neoplasms

KW - Polycystic ovary syndrome

KW - Uterine cervical neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85087445676&partnerID=8YFLogxK

U2 - 10.2174/0929867326666190104124245

DO - 10.2174/0929867326666190104124245

M3 - Review article

C2 - 30608036

AN - SCOPUS:85087445676

VL - 27

SP - 3611

EP - 3622

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 22

ER -

ID: 87784368